GC Biopharma Corp. Obtains Egyptian Product Approval for Influenza Vaccine ‘GC Flu’

This is the first time the company’s quadrivalent influenza vaccine has received product approval in the African continent.

GC Flu, the leading vaccine product of GC Biopharma Corp., is a product that has been recognized internationally for its safety and effectiveness, as it continues to expand its export countries and volumes every year based on the company’s globally verified influenza vaccine manufacturing technology.

The company plans to expand its global territory further in the African and Middle Eastern regions based on this product approval in Egypt, in addition to the existing flu vaccine markets in Southeast Asia and Central and South America. It also plans to drive into individual national private markets based on its foothold in the international procurement market it has built up so far.